title: [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
abstract: BACKGROUND
  Pergolide mesilate is widely used to treat Parkinson's disease in both the USA and Japan, but the maintenance dose is distinctly different between the USA (usually more than 1.5 mg/day) and Japan (usually less than 1.5 mg/day). Although several reports from the USA have suggested that mitral, aortic, and tricuspid valvular lesions were caused by pergolide, it is unclear whether low-dose pergolide therapy causes such valvular lesions.
  
  
  OBJECTIVE
  The effects of low-dose pergolide therapy on cardiac valves were studied in Japanese patients with Parkinson's disease.
  
  
  METHODS
  One hundred and five consecutive patients with Parkinson's disease approved for our protocol were enrolled in this study. Forty patients were treated with low-dose pergolide (0.05-1.5 mg/day for 2-115 months), and were included in the pergolide group (mean age 71 +/- 6 years). The other 44 patients received no ergot-derived dopamine receptor agonists, and 32 patients acted as age-matched controls (mean age 71 +/- 7 years). Both groups of patients underwent echocardiographic examination to detect organic lesions in cardiac valves such as thickening of the leaflet, annular calcification, restriction of valve motion and valvular tenting, and valvular regurgitation greater than 2 + on the 4-point scale.
  
  
  RESULTS
  No significant difference was observed in the incidence of aortic, mitral and pulmonic valve lesions between the pergolide group and the control group. Although no organic lesions were detected in the tricuspid valve, the incidence of tricuspid regurgitation was significantly higher in the pergolide group than in the control group (p < 0.05).
  
  
  CONCLUSIONS
  Although low-dose pergolide of less than 1.5 mg/day does not cause serious damage in the left-sided valves, it may induce tricuspid regurgitation.
authors.affiliation: Kashiwaba Neurosurgical Hospital, Sapporo. labo@kashiwaba-nougeka.or.jp
authors.forename: Mutsuko
authors.initials: M
authors.lastname: Muraki
authors.forename: Taisei
authors.initials: T
authors.lastname: Mikami
authors.forename: Mayumi
authors.initials: M
authors.lastname: Kitaguchi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Sugawara
authors.forename: Katsuyoshi
authors.initials: K
authors.lastname: Isonishi
authors.forename: Sadao
authors.initials: S
authors.lastname: Kaneko
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kashiwaba
authors.forename: Fumio
authors.initials: F
authors.lastname: Moriwaka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yamada
authors.forename: Hisao
authors.initials: H
authors.lastname: Onozuka
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Tsutsui
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D015150:Echocardiography, Doppler; D005260:Female; D006351:Heart Valves / Q000000981:diagnostic imaging* / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010479:Pergolide / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000978:Antiparkinson Agents; D010479:Pergolide